Business Wire

DIGITAL-ELEMENT

25.6.2019 10:04:04 CEST | Business Wire | Press release

Share
ClickFellas Chooses Digital Element to Increase Accuracy of IP Geotargeting Services

Digital Element , the global geolocation data and services provider, today announced that ClickFellas, a new advertising technology company, has chosen its NetAcuity EdgeTM technology to improve ad targeting for its clients.

By incorporating Digital Element’s technology, ClickFellas is able to identify the consumer’s location, internet service provider, connection speed, mobile carrier, organisation name and proxy type without the user becoming personally identifiable. This highly accurate and granular IP data is used to facilitate standalone geotargeting and, when combined with additional factors such as gender, purchase intent and history data, allows Clickfellas to create tighter targeting profiles. Additionally, proxy data is used to help combat click fraud.

“Digital Element’s technology helps us not only improve the accuracy of geotargeted advertising being served but also, ensures that we limit fraudulent traffic,” commented Franz Kanehl, Co-Founder ClickFellas Ltd. “For us, the biggest value in Digital Element’s data is the accuracy it provides. By using NetAcuity Edge technology we are able to include hyper local targeted campaigns into our portfolio, to generate increased earnings for our clients through contextually relevant advertising.”

“Digital Element is the industry leader for IP geolocation intelligence and their superior performance over competitors is clear. With some of the biggest brands in the industry choosing to use Digital Element’s technology, we didn’t want to miss out!“

Digital Element’s NetAcuity Edge combines traditional infrastructure analysis with insight gleaned from a network of global commercial partners to better map the internet. The result is the most granular and accurate hyperlocal geotargeting solution that maintains user anonymity and complies with the highest standards of end-user privacy.

“We are thrilled ClickFellas has decided to choose our NetAcuity Edge technology and are confident that our tools will provide their clients with the best data to create suitably targeted campaigns,” said Kate Owen, Digital Element’s Vice President, Northern Europe. “Compared to other solutions in the market, Digital Element provides highly accurate data that covers the entire internet, and a high number of datasets encompassing more than location. This allows ClickFellas to deliver the right message to the right user at the right time. ClickFellas is an innovative, forward-looking new company and we are excited to work with them to exceed their objectives as a result of using our services.”

ClickFellas joins Digital Element’s portfolio of high-profile clients, which includes: Adobe, Facebook, Pinterest, LinkedIn, Codewise, Videology, Invidi/Ooyala, MediaMath, Adform, BBC, Discovery Networks, Hubspot, Vibrant Media, Webtrends, Crimtan, Weborama, Ogilvy and many others.

About Digital Element

Since 1999, Digital Element has been providing global geolocation data and services that bring anytime, anywhere relevance and context to online initiatives—from desktops to mobile devices. The company’s patented technology has been certified and accredited to deliver real-time access to accurate and reliable location intelligence without invading Internet users’ privacy. For nearly two decades, many of the world’s largest websites, brands, security companies, ad networks, social media platforms and mobile publishers have trusted Digital Element’s technology to target advertising, localize content, enhance analytics, and manage content rights as well as detect and prevent fraud.

Visit http://www.digitalelement.com for more information on how to bring the power of location to the online world. Follow us on LinkedIn and Twitter @DigitalElement then like us on Facebook .

Headquartered in Atlanta and London, Digital Element is a division of Digital Envoy Inc .

About ClickFellas

ClickFellas operate as a media-buying network using qualitative predictive algorithms to provide detailed insights into consumers for advertisers to target campaigns towards. Working with a variety of providers from leading data providers to media management platforms, ClickFellas mission is to consistently drive results and targets for their clients.

Visit www.clickfellas.com for more information.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye